Tetra Tech reports its Q2 fiscal 2026 results today with short sellers notably less aggressive than they were two weeks ago.
Short interest has retreated sharply from its recent peak. It hit roughly 4.9% of the float in mid-April before pulling back to 4.4% — a 9% drop over the past week alone. That de-risking by bears coincides with a recovering stock price, which is up 7% over the past month to $31.87. The borrow market reinforces the picture: cost to borrow is negligible at 0.45%, and availability is wide open, meaning there is no squeeze pressure bearing down on existing short positions. The ORTEX short score has also drifted lower, falling from around 41 a week ago to 39.3, a mid-range reading that signals no particular conviction from either side.
Options positioning is more interesting than the short interest story. The put/call ratio has eased meaningfully into the print — running at 2.67, it is more than two standard deviations below its 20-day average of 2.84, the least defensive options posture in recent weeks. That drop is notable given how structurally elevated the PCR has been all month. It suggests options traders have been unwinding protective puts rather than adding fresh hedges into today's release.
The analyst debate centres on margin trajectory and government contract exposure. Bulls point to Tetra Tech's projected 6–10% organic growth for fiscal 2026 and the non-recurrence of lower-margin USAID projects, which underpins expectations for a 60–70 basis point year-over-year margin improvement. Bears flag the company's reliance on government contracts — subject to termination or revision — alongside fixed-price contract risk and potential headwinds from a softer macro backdrop. The most recent analyst data available is from November 2025, when RBC Capital held its Outperform rating with a $48 target and Baird maintained Neutral at $41. Both sit well above the current price, which is down sharply from where those targets were set, so the gap carries less informational weight than it might otherwise. Consensus is a hold, with a mean target of $41.17 — implying around 29% upside from current levels, though that figure reflects a period before the recent price decline.
Capital Research and Management added roughly 2 million shares as of March 31 — the largest institutional change in the recent filing round — bringing its stake to just over 4.3% of shares outstanding. That is a meaningful accumulation from an active manager and signals at least one major holder adding exposure ahead of the print.
Today's report will test whether the margin improvement thesis has held up under government budget uncertainty, and whether organic growth guidance for the remainder of fiscal 2026 remains intact.
See the live data behind this article on ORTEX.
Open TTEK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
